Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $182.61 USD
Change Today +1.84 / 1.02%
Volume 789.9K
ALXN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:37 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

alexion pharmaceuticals inc (ALXN) Snapshot

Open
$182.59
Previous Close
$180.77
Day High
$184.63
Day Low
$181.00
52 Week High
12/3/14 - $203.30
52 Week Low
05/6/15 - $150.06
Market Cap
40.3B
Average Volume 10 Days
3.0M
EPS TTM
$3.12
Shares Outstanding
220.6M
EX-Date
--
P/E TM
58.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for ALEXION PHARMACEUTICALS INC (ALXN)

alexion pharmaceuticals inc (ALXN) Related Businessweek News

View More BusinessWeek News

alexion pharmaceuticals inc (ALXN) Details

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft versus host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.

2,273 Employees
Last Reported Date: 02/6/15
Founded in 1992

alexion pharmaceuticals inc (ALXN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $696.1K
Co-Founder, Chairman of The Board and Consult...
Total Annual Compensation: $1.3M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $715.0K
Global Head of Research & Development and Exe...
Total Annual Compensation: $650.0K
Chief Strategy & Portfolio Officer and Execut...
Total Annual Compensation: $325.0K
Compensation as of Fiscal Year 2014.

alexion pharmaceuticals inc (ALXN) Key Developments

Alexion Pharmaceuticals, Inc. Enters into Credit Agreement

Alexion Pharmaceuticals, Inc. entered into a Credit Agreement by and among Alexion, as Administrative Borrower, certain foreign subsidiaries, as borrowers thereto, the lenders referred to therein and Bank of America, N.A., as Administrative Agent. Pursuant to the Credit Agreement, the company borrowed term loans in an aggregate amount of USD 3.50 billion. In addition, the Credit Agreement provides for a USD 500 million revolving facility, USD 200 million of which was drawn at closing. The Credit Agreement matures on June 22, 2020. The proceeds of the borrowing under the Credit Agreement were used to finance the purchase of the shares, refinance certain existing indebtedness of the company and its subsidiaries and to pay fees and expenses incurred in connection with the foregoing. The loans will bear interest, at Alexion's option, at either a base rate or a Eurodollar rate, in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.25% to 1.00% and the applicable margins on Eurodollar loans range from 1.25% to 2.00%, in each case based on Alexion's consolidated net leverage ratio. Under the terms of the Credit Agreement, Alexion must maintain a ratio of total net debt to EBITDA of 3.75 to 1.00, in the case of each such fiscal quarter ending on or prior to September 30,2016 or 3.50 to 1.00, in the case of each such fiscal quarter ending after September 30, 2016, subject to certain increases following designated material acquisitions. In addition, the company must maintain a ratio of EBITDA to cash interest expense of at least 3.50 to 1.00.

Felix Baker Joins Alexion Board of Directors

Alexion Pharmaceuticals, Inc. announced that it has successfully completed its previously announced acquisition of Synageva BioPharma Corp. The transaction was completed through a merger of Synageva with and into a direct, wholly owned subsidiary of Alexion. Following the acquisition, Dr. Felix Baker, former Chairman of the Board of Synageva, will join the Alexion Board of Directors, effective from June 23, 2015.

Alexion Pharmaceuticals, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 12:10 PM

Alexion Pharmaceuticals, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 12:10 PM. Venue: Four Seasons Hotel, Chicago, Illinois, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $182.49 USD +1.72

ALXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Croda International PLC 2,778 GBp +26.00
Dr Reddy's Laboratories Ltd 3,574 INR +14.15
Sigma-Aldrich Corp $139.45 USD +0.10
Symrise AG €56.11 EUR +0.364
United Therapeutics Corp $173.51 USD -0.44
View Industry Companies
 

Industry Analysis

ALXN

Industry Average

Valuation ALXN Industry Range
Price/Earnings 61.9x
Price/Sales 15.9x
Price/Book 10.3x
Price/Cash Flow 69.3x
TEV/Sales 17.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit www.alexionpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.